Live
FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune systemFierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseasesEndpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesBioPharma DiveLilly, Ascidian link up in RNA exon editing pactCellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorinsCellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defenseLabiotechSurge in M&As driven by patent expirationsThermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum AsiaeLifeHSD17B7 is required for the function of sensory hair cells by regulating cholesterol synthesisBioPharma DiveCelcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialClinical OMICsAI-Powered Blood Test Detects Early Retinal Damage in DiabetesClinical OMICsMature Intestinal Cells Revert to Stem-Like State to Sustain Colorectal Cancer
FierceBiotech Apr 13, 2026

FDA urges clinical trial sponsors to report the results of their studies

FDA urges clinical trial sponsors to report the results of their studies

Original
Body unavailable. Use the original source.